Abbott Laboratories
ABTNYSEHealthcare● Active
$90.56
$-0.51(-0.56%)
Market Cap$157.7B
P/E Ratio—
52W High$139.06
52W Low$81.97
Abbott Laboratories (ABT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ABT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 16, 2026EPS Actual
$1.15
Est. $1.14 · +0.9%
Revenue
$11.16B
Est. $11.00B · +1.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 16, 2026
After Market Close
▲ Beat Revenue🔥 11-Quarter EPS Beat Streak
ABT reports quarterly as a NYSE-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 16, 2026 | $1.28 | — | — | — | $12.54B | — |
| — Q2 FY2026 | Apr 16, 2026 | $1.14 | $1.15 | +0.9% | $11.16B | $11.00B | +1.5% |
| — Q1 FY2026 | Jan 22, 2026 | $1.50 | $1.50 | +0.0% | $11.46B | $11.80B | -2.9% |
| — Q4 FY2025 | Oct 15, 2025 | $1.30 | $1.30 | +0.0% | $11.37B | $11.39B | -0.2% |
| — Q3 FY2025 | Jul 17, 2025 | $1.26 | $1.26 | +0.0% | $11.14B | $11.09B | +0.5% |
| ▲ Q2 FY2025 | Apr 16, 2025 | $1.07 | $1.09 | +1.9% | $10.36B | $10.41B | -0.5% |
| — Q1 FY2025 | Jan 22, 2025 | $1.34 | $1.34 | +0.0% | $10.97B | $11.03B | -0.5% |
| — Q4 FY2024 | Oct 16, 2024 | $1.20 | $1.21 | +0.8% | $10.63B | $10.55B | +0.8% |
Q3 FY2026
Jul 16, 2026
EPS Actual
—
EPS Est.
$1.28
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 16, 2026
EPS Actual
$1.15
EPS Est.
$1.14
EPS Surpr.
+0.9%
Revenue
$11.16B
Q1 FY2026
Jan 22, 2026
EPS Actual
$1.50
EPS Est.
$1.50
EPS Surpr.
+0.0%
Revenue
$11.46B
Q4 FY2025
Oct 15, 2025
EPS Actual
$1.30
EPS Est.
$1.30
EPS Surpr.
+0.0%
Revenue
$11.37B
Q3 FY2025
Jul 17, 2025
EPS Actual
$1.26
EPS Est.
$1.26
EPS Surpr.
+0.0%
Revenue
$11.14B
Q2 FY2025
Apr 16, 2025Beat
EPS Actual
$1.09
EPS Est.
$1.07
EPS Surpr.
+1.9%
Revenue
$10.36B
Q1 FY2025
Jan 22, 2025
EPS Actual
$1.34
EPS Est.
$1.34
EPS Surpr.
+0.0%
Revenue
$10.97B
Q4 FY2024
Oct 16, 2024
EPS Actual
$1.21
EPS Est.
$1.20
EPS Surpr.
+0.8%
Revenue
$10.63B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.86 | $1.89 | $1.91 | 7 |
| Q3 FY2028 | $1.72 | $1.75 | $1.77 | 12 |
| Q2 FY2028 | $1.60 | $1.62 | $1.65 | 7 |
| Q1 FY2028 | $1.47 | $1.49 | $1.51 | 7 |
| Q4 FY2027 | $1.71 | $1.74 | $1.76 | 6 |
| Q3 FY2027 | $1.56 | $1.58 | $1.60 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $15.4B | $15.6B | $15.7B | 6 |
| Q3 FY2028 | $14.9B | $15.1B | $15.3B | 6 |
| Q2 FY2028 | $14.3B | $14.5B | $14.6B | 6 |
| Q1 FY2028 | $13.6B | $13.8B | $13.9B | 6 |
| Q4 FY2027 | $14.4B | $14.5B | $14.7B | 7 |
| Q3 FY2027 | $13.9B | $14.1B | $14.2B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 16, 2026 | +0.9% | $101.56 | $95.47 | -6.00% |
| ▲ Q1 FY2026 | Jan 22, 2026 | +0.0% | $120.73 | $108.61 | -10.04% |
| ▲ Q4 FY2025 | Oct 15, 2025 | +0.0% | $133.27 | $129.45 | -2.87% |
| ▲ Q3 FY2025 | Jul 17, 2025 | +0.0% | $131.74 | $120.51 | -8.52% |
| ▲ Q2 FY2025 | Apr 16, 2025 | +1.9% | $126.22 | $129.70 | +2.76% |
| ▲ Q1 FY2025 | Jan 22, 2025 | +0.0% | $116.79 | $117.78 | +0.85% |
| ▲ Q4 FY2024 | Oct 16, 2024 | +0.8% | $116.05 | $117.82 | +1.53% |
| ▲ Q3 FY2024 | Jul 18, 2024 | +3.6% | $104.68 | $100.07 | -4.40% |
Q2 FY2026-6.00%
Report Date
Apr 16, 2026
EPS Beat/Miss
+0.9%
Price Before
$101.56
Price After
$95.47
Q1 FY2026-10.04%
Report Date
Jan 22, 2026
EPS Beat/Miss
+0.0%
Price Before
$120.73
Price After
$108.61
Q4 FY2025-2.87%
Report Date
Oct 15, 2025
EPS Beat/Miss
+0.0%
Price Before
$133.27
Price After
$129.45
Q3 FY2025-8.52%
Report Date
Jul 17, 2025
EPS Beat/Miss
+0.0%
Price Before
$131.74
Price After
$120.51
Q2 FY2025+2.76%
Report Date
Apr 16, 2025
EPS Beat/Miss
+1.9%
Price Before
$126.22
Price After
$129.70
Q1 FY2025+0.85%
Report Date
Jan 22, 2025
EPS Beat/Miss
+0.0%
Price Before
$116.79
Price After
$117.78
Q4 FY2024+1.53%
Report Date
Oct 16, 2024
EPS Beat/Miss
+0.8%
Price Before
$116.05
Price After
$117.82
Q3 FY2024-4.40%
Report Date
Jul 18, 2024
EPS Beat/Miss
+3.6%
Price Before
$104.68
Price After
$100.07
Avg Beat Reaction-3.34%
Beat Rate8 / 8 quarters
Largest Move-10.04% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ABT ends December
Abbott Laboratories (ABT) most recently reported earnings on April 16, 2026 for Q2 FY2026, posting EPS of $1.15 (in line with the analyst consensus of $1.14). ABT has beaten EPS estimates for 11 consecutive quarters. The next ABT earnings date is expected around September 1, 2026.
Each quarter, investors track ABT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ABT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ABT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ABT earnings · 4 questionsAbbott Laboratories's next earnings report is expected around September 1, 2026. ABT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ABT historically reports after market close (AMC).
ABT earnings datewhen is ABT earningsABT next earnings datewhen does ABT report earningsABT earnings calendar
▸ Source: FMP · Abbott Laboratories SEC filings · US GAAP · Abbott Laboratories SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026